Cartalax 20mg

£41.90

Cartalax is a synthetic tripeptide used as a research tool to investigate tissue-specific gene-expression regulation in cartilage and connective-tissue experimental systems.

  • OP Labs formerly Oxford Peptides
  • Batch tested Purity: ≥ 99% (HPLC)
  • CAS Number: N/A
  • Molecular Formula: C12H19N3O8
  • Amino Acid Sequence: Ala-Glu-Asp (AED)

In stock

Add to Cart
Cartalax 20mg
Cartalax 20mg
£41.90
  • Royal Mail Tracked24
  • Order before 16.00 for same day dispatch
  • Dedicated customer support

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies are performed outside of the body. These products are not medicines or drugs and have not been approved to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden.

  • OP Labs formerly Oxford Peptides
  • Batch HPLC tested at ≥ 99% purity
  • Storage: –20 °C long term; 2–8 °C short term
  • Sold for research purposes only

Cartalax

Synonyms / Designations: Cartalax; AED
Amino Acid Sequence: Ala-Glu-Asp (AED)
CAS Number: N/A
Molecular Formula: C12H19N3O8
Molecular Weight: 333.30 g/mol
Purity: ≥ 99% (HPLC)
Appearance: White to off-white lyophilised powder
Pack Size: 20 mg (total)
Storage: Desiccated, protected from light, stored at –20 °C or below
Solubility: Soluble in water and buffered aqueous solutions

Description & Mechanism

Cartalax is a short synthetic tripeptide used as a molecular probe for studying tissue-specific gene regulation in cartilage and connective-tissue model systems. In chondrocyte and fibroblast cultures it has been used to examine effects on cell proliferation, apoptosis and expression of extracellular-matrix genes (e.g. type II collagen, aggrecan).

In molecular-docking work, the AED motif is assigned to a specific promoter site, supporting its use as a research probe for putative short-peptide / DNA-promoter interactions. It is studied as a candidate transcriptional regulator in experimental musculoskeletal systems; observed effects depend on concentration, model system and exposure conditions.

Applications in Research

  • In-vitro chondrocyte and fibroblast proliferation / apoptosis assays
  • Extracellular-matrix gene-expression studies (collagen II, aggrecan)
  • Probe for short-peptide promoter-binding studies

Specifications Summary

ParameterTypical Value / Range
Purity (HPLC)≥ 99%
AppearanceWhite to off-white lyophilised powder
Molecular Weight333.30 g/mol
Peptide TypeSynthetic linear tripeptide
SolubilityWater, buffered aqueous solutions
Storage–20 °C, desiccated, dark
Pack Size20 mg (total)

Precautions & Notes

  • Experimental behaviour is dependent on concentration, model system and exposure conditions
  • Appropriate experimental controls are recommended
  • Prolonged exposure to light, elevated temperature or aqueous environments may reduce stability
  • Intended strictly for laboratory research use; not for human or veterinary application

References

Khavinson VKh, Linkova NS, Tarnovskaya SI, et al. Short cell-penetrating peptides: a model of interactions with gene promoter sites. Bull Exp Biol Med.
https://pubmed.ncbi.nlm.nih.gov/23484211/

Short Peptides Regulate Gene Expression. Bull Exp Biol Med. 2016.
https://link.springer.com/article/10.1007/s10517-016-3596-7

Khavinson VKh, Popovich IG, et al. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053.
https://www.mdpi.com/1420-3049/26/22/7053

Keywords: Cartalax, AED, synthetic tripeptide